Evidence map›Paper›PMID 41591707›Full record

ArticleBreast cancer (Tokyo, Japan)2026

Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).

Shigenori E Nagai, Masaya Hattori, Tetsuhiro Yoshinami, Hiroko Masuda, Takuho Okamura, Kenichi Watanabe, Takahiro Nakayama, Michiko Tsuneizumi, Daisuke Takabatake, Michiko Harao and 13 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Shigenori E NagaiDivision of Breast Oncology, Saitama Prefectural Cancer Center, Saitama, Japan.ORCID http://orcid.org/0000-0003-2887-6066
Masaya HattoriDepartment of Breast Oncology, Aichi Cancer Center, Nagoya, Japan.
Tetsuhiro YoshinamiDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Hiroko MasudaDepartment of Breast Surgical Oncology, School of Medicine, Showa University, Tokyo, Japan.
Takuho OkamuraDepartment of Breast Oncology, Tokai University School of Medicine, Tokyo, Japan.
Kenichi WatanabeDepartment of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
Takahiro NakayamaDepartment of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan.
Michiko TsuneizumiDepartment of Breast Surgery, Shizuoka General Hospital, Shizuoka, Japan.
Daisuke TakabatakeDepartment of Breast Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Michiko HaraoDepartment of Breast Oncology, Jichi Medical University, Shimotsuke, Japan.
Hiroshi YoshinoBreast and Endocrinological Surgery, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
Natsuko MoriDepartment of Breast Surgery, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
Hiroyuki YasojimaDepartment of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Chiya OshiroDepartment of Breast Surgery, Kaizuka City Hospital, Osaka, Japan.
Madoka IwaseDepartment of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Japan.
Miki YamaguchiDepartment of Breast Surgery, JCHO Kurume General Hospital, Kurume, Japan.
Takafumi SangaiDepartment of Breast and Thyroid Surgery, Kitasato University School of Medicine, Sagamihara, Japan.
Shinsuke SasadaDepartment of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Takanori IshidaDivision of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Manabu FutamuraDepartment of Breast Surgery, Gifu University Hospital, Gifu, Japan.
Yasuaki MuramatsuOncology Medical Affairs, Pfizer Japan Inc, Tokyo, Japan.
Nobuyoshi KosakaOncology Medical Affairs, Pfizer Japan Inc, Tokyo, Japan.ORCID http://orcid.org/0000-0001-5571-261X
Norikazu MasudaDepartment of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-Cho, Sakyo-Ku, Kyoto, 606-8507, Japan. nmasuda@alpha.ocn.ne.jp.ORCID http://orcid.org/0000-0002-7302-0278

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41591707
PMCPMC12960297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.